Radnostix Reports Sharply Increased Q1 Loss, Revenue Decline Amid Product Recalls and Terminated Asset Sale

summarizeSummary

Radnostix Inc. announced a significantly wider net loss and lower revenue in Q1 2026, impacted by product recalls and the termination of a major asset sale, highlighting ongoing financial and operational challenges.

check_boxKey Events

• Net Loss Surges

  Net loss for Q1 2026 increased to $1.35 million, a 1,096% increase compared to a net loss of $0.11 million in Q1 2025.

• Revenue Declines Significantly

  Total product sales decreased by 27% to $2.38 million in Q1 2026 from $3.24 million in the same period last year.

• Product Recalls Impact Sales

  Two voluntary product recalls in Q1 2026 resulted in $60,000 in lost revenue from one batch, an ongoing $65,000 weekly sales loss, $50,000 in customer credits, and a $75,000 inventory write-off.

• $12.5M Asset Sale Terminated

  The company mutually terminated a $12.5 million asset purchase agreement for its Fluorine Products segment and Uranium De-Conversion Facility on March 11, 2026, citing low confidence in the buyer's funding. This was previously announced in an 8-K on March 16, 2026.

auto_awesomeAnalysis

Radnostix Inc. reported a substantial increase in net loss and a significant drop in revenue for Q1 2026, driven by product recalls and operational shutdowns. The termination of a $12.5 million asset sale further exacerbates liquidity concerns, despite a temporary extension of preferred stock redemption. The company continues to face supply chain challenges and regulatory scrutiny from the FDA.